Top searches

PL

Resources

B2RLaw advises biotech company Ambulero on fundraising

27/01/2021

B2RLaw has advised Ambulero, Inc., a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease on funding of up to USD 5.5 million received from from Orphinic Scientific.

As part of the investment, and with the help of B2RLaw, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. z o.o.) that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. The disease is rare in the US but more common in certain parts of Central and Eastern Europe.

Ambulero is a biotechnology company dedicated to advancing a platform of cell and gene therapies to treat serious vascular diseases. The company is a 2019 spin-out of the University of Miami co-founded by Robert L. Buchanan, Randy Berholtz, Omaida C. Velazquez and Jun Zhao-Liu. It holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. Omaida C. Velazquez and Jun Zhao-Liu.

With offices in Palo Alto, California and Warsaw, Poland, Orphinic Scientific is an innovative drug development and investment company focused on mid-market opportunities and orphan drugs in late preclinical research and Phase 1 or 2.

B2RLaw’s team was led by Partner Szymon Syp and included Senior Associate Iga Wojtczak – Opala and Junior Associate Jakub Niemiec.

Szymon Syp advises, “We congratulate Ambulero and Orphinic Scientific on this transaction. Ambulero’s important work means that people that suffer from serious vascular disease (which at best, causes severe discomfort and at worst, can result in death) can live in comfort with the knowledge that innovative treatment is on the horizon. We wish Ambulero the best of luck on its future clinical testing”.

View more resources

Catch up on the very latest B2RLAW
announcements and news here.

09/06/2021

Edyta Zalewska joins B2RLaw’s Partnership, and six lawyers are promoted

B2RLaw has announced Edyta Zalewska as Partner in its 2021 promotion round, effective as of 1st May 2021. B2RLaw is also […]

MORE
11/05/2021

B2RLaw shortlisted as a finalist of the PSIK Awards 2021 for Venture Capital Legal Advisor of the Year

B2RLaw is pleased to advise that it has been selected as a finalist of the PSIK Awards 2021 for Venture […]

MORE
26/04/2021

B2RLaw advises PGNiG Ventures on investment in electromobility charger company Enelion

B2RLaw has advised PGNiG Group’s corporate venture capital fund on its investment in Enelion, a provider of comprehensive solutions for […]

MORE
25/04/2021

On the Ropes: Anti-Corruption and International Risk Perspectives from Recent Developments in Poland

In this edition of Ropes & Gray’s podcast series On the Ropes: Enforcement Risk Roundtable, litigation and enforcement partner, Amanda […]

MORE
01/04/2021

B2RLaw advises Henley Investments on its debut Polish acquisition of a shopping centre

B2RLaw has advised Henley Investments, a leading private equity real estate firm based in the UK, on the acquisition of […]

MORE
23/03/2021

B2RLaw advises specialist international food and agribusiness PE fund on investment

B2RLaw has advised Paine Schwartz Partners, a global leader in investments in the food and agribusiness sectors, on its investment […]

MORE

Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close